Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 2—February 2019

Oasis Malaria, Northern Mauritania1

Jemila Deida, Rachida Tahar, Yacoub Ould Khalef, Khadijetou Mint Lekweiry, Abdoullah Hmeyade, Mohamed Lemine Ould Khairy, Frédéric Simard, Hervé Bogreau, Leonardo Basco, and Ali Ould Mohamed Salem BoukharyComments to Author 
Author affiliations: Unité Mixte de Recherche 216, Institut de Recherche pour le Développement, Université Paris 5, Sorbonne Paris Cité, Paris, France (J. Deida, R. Tahar); Université de Nouakchott Al-Aasriya, Nouakchott, Mauritania (J. Deida, K. Mint Lekweiry, A. Ould Mohamed Salem Boukhary); Ministry of Health, Nouakchott (Y. Ould Khalef, M.L. Ould Khairy); Ministry of Health, Atar (A. Hmeyade); Maladies Infectieuses et Vecteurs: Ecologie, Génétique, Evolution et Contrôle, Institut de Recherche pour le Développement–Centre National de Recherche Scientifique– Université Montpellier, Montpellier, France (F. Simard); Institut de Recherche Biomédicale des Armées, Marseille (H. Bogreau); Centre National de Référence du Paludisme, Marseille (H. Bogreau); Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique–Hôpitaux de Marseille, Service de Santé des Armées, Vecteurs–Infections Tropicales et Méditerranéennes, Marseille, France (H. Bogreau, L. Basco, A. Ould Mohamed Salem Boukhary)

Main Article

Table 3

Performance of rapid diagnostic testing and microscopic examination in establishing malaria diagnosis in 453 febrile patients, using PCR as reference standard, Atar, northern Mauritania, 2015–2016*

Performance % (95% CI)†
Rapid diagnostic test
Microscopic examination
Pv Pf Pv–Pf Pv Pf Pv–Pf
Sensitivity 63.3 (55.3–70.8) 28.6 (15.7–44.6) 66.0 (58.2–73.3) 82.9 (76.1–88.4) 4.8 (0.6–16.2) 91.4 (85.9–95.2)
Specificity 99.3 (97.6–99.9) 99.0 (97.5–99.7) 99.7 (98.1–99.9) 96.9 (94.3–98.6) 99.5 (98.3–99.9) 97.9 (95.6–99.2)
PPV 98.0 (92.6–99.5) 75.0 (50.3–89.9) 99.1 (93.8–99.9) 93.6 (88.4–96.5) 50.0 (12.6–87.4) 96.1 (91.8–98.2)
NPV 83.5 (80.4–86.1) 93.1 (91.8–94.3) 84.1 (81.0–86.7) 91.4 (88.2–93.7) 91.1 (90.5–91.6) 95.3 (92.5–97.1)
Accuracy 86.8 (83.3–89.7) 92.5 (89.7–94.7) 87.6 (84.2–90.5) 92.1 (89.2–94.4) 90.7 (87.7–93.2) 95.6 (93.3–97.3)

*NPV, negative predictive value; Pf, pure P. falciparum plus mixed P. falciparum–P. vivax; PPV, positive predictive value; Pv, pure P. vivax plus mixed P. falciparum–P. vivax; Pv–Pf, pure P. vivax plus pure P. falciparum plus mixed P. falciparum–P. vivax.
†Percentages of PCR-positive patients (i.e., the percentage of positives for different Plasmodium spp. among included patients [n = 435]), were as follows: 34.9% (95% CI 30.5%–39.5%) for pure P. vivax; 9.3% (95% CI 6.8%–12.3%) for pure P. falciparum; and 35.8% (95% CI 31.3%–40.4%) for P. vivax–P. falciparum mixed infections. PCR showed that none of the samples had P. ovale or P. malariae.

Main Article

1Preliminary results of this study were presented at the 7th Multilateral Initiative for Malaria (MIM) Pan African Malaria Conference, April 15–20, 2018, Dakar, Senegal.

Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.